|
Below you will find a full overview of Crucell’s R&D partners and licensees
Latest update: November 22, 2010 |
| |||||||||||||||
Vaccines
|
Partner/ Licensee |
Starting date |
Technology platform |
Area |
Development stage | |||||||
|
Mar. 2004 |
PER.C6® + AdVac® |
Tuberculosis |
| ||||||||
|
Bestewil Holding BV |
Jan. 2006 |
Co-micelles |
| ||||||||
|
Harvard School of Medicine |
Dec. 2003 |
AdVac® + Ad5HVR48 |
| ||||||||
|
International AIDS Vaccine Initiative (IAVI) |
Sep. 2004 |
AdVac®
|
HIV |
| |||||||
|
Kimron Veterinary Institute |
|
July 2003 |
|
PER.C6® |
|
West Nile Virus Veterinary vaccine (avian) |
|
Marketed in Israel | |||
|
Merck & Co. Inc. |
Nov. 1998 |
PER.C6® |
Undisclosed vaccines |
 | |||||||
|
Merck & Co. Inc. |
|
Dec. 2006 |
|
PER.C6® + AdVac® |
|
2 infectious disease areas |
|
| |||
|
National Institutes of Health (NIH) |
|
Mar. 2002 |
|
PER.C6® + AdVac® |
|
|
| ||||
|
National Institutes of Health (NIH) |
|
Mar. 2004 |
|
PER.C6® + AdVac® |
|
|
| ||||
|
Okairos Srl. |
|
Oct. 2006 |
|
PER.C6® |
|
Hepatitis C |
|
| |||
|
TapImmune Inc. |
|
Nov. 2008 |
|
PER.C6® |
|
Undisclosed vaccine |
|
| |||
|
Transgene SA |
|
Dec. 2007 |
|
PER.C6® |
|
Undisclosed vaccine |
|
| |||
| Transgene | Jan. 2010 |
PER.C6® |
Infectious diseases |
| |||||||
|
Vaxin, Inc. |
|
Sep. 2004 |
|
PER.C6® |
|
Alzheimers disease and veterinary |
|
| |||
Proteins
|
Partner/ Licensee |
|
Starting date |
|
Technology platform |
|
Area |
|
Development stage | ||
| Abraxis Bioscience, LLC. | Oct. 2008 |
PER.C6® |
Protein production |  | ||||||
| Affitech A.S. | Nov. 2008 |
PER.C6® |
Undisclosed antibodies | | ||||||
| Bioceros B.V. | May 2008 |
STAR® |
Portfolio antibodies |
| ||||||
| Biotecnol S.A. | Jan. 2007 |
PER.C6® |
Portfolio antibodies | | ||||||
| Cangene Corp. | Oct. 2008 |
PER.C6® |
Undisclosed antibodies |
| ||||||
| Centocor Inc. | Dec. 2008 |
STAR® |
Monoclonal antibodies | | ||||||
| CSL Ltd. | Dec. 2008 |
PER.C6® |
Undisclosed protein | | ||||||
| Daiichi Sankyo Co. Ltd. | Nov. 2007 |
PER.C6® |
Portfolio antibodies | | ||||||
|
Ferring International Center SA |
May 2005 |
PER.C6® |
Women’s healthcare |
| ||||||
|
Ferring International Center S.A. |
Dec. 2005 |
PER.C6® |
Women’s healthcare |
| ||||||
| Gedeon Richter PLC | Nov. 2008 |
PER.C6® |
Undisclosed biopharmaceutical | | ||||||
|
GlaxoSmithKline Biologicals SA |
Dec. 2008 |
PER.C6® |
protein |
| ||||||
|
IQ Corporation B.V. |
Oct. 2005 |
PER.C6® |
Anti-anthrax antibody |
| ||||||
|
LFB Biotechnologies |
July 2007 |
PER.C6® |
Undisclosed antibodies | | ||||||
|
Merus B.V. |
Jun. 2004 |
PER.C6® |
Portfolio oligoclonics |
| ||||||
|
MorphoSys A.G. |
Aug. 2004 |
PER.C6® |
Portfolio antibodies |
| ||||||
| MorphoSys A.G. | Aug. 2006 |
PER.C6® |
Inflammatory diseases |
| ||||||
|
MorphoSys A.G. |
Apr. 2008 |
PER.C6® |
Oncology | | ||||||
| NeoPharm Co. Ltd | Apr. 2010 |
PER.C6® |
Recombinant proteins and antibodies | | ||||||
| Oy Medix Biochema AB | Dec. 2009 |
PER.C6® |
Recombinant antibodies | | ||||||
| Patrys Ltd. | July. 2009 |
PER.C6® |
Monoclonal antibodies | | ||||||
| Patrys Ltd. | Feb. 2007 |
PER.C6® |
Undisclosed protein |
| ||||||
|
PR&D Biotech S.A. |
Oct. 2007 |
PER.C6® |
Undisclosed protein |
| ||||||
| ProFibrix B.V. | Dec. 2008 |
PER.C6® |
Recombinant fibrinogen | | ||||||
|
ProFibrix B.V. |
Dec. 2008 |
PER.C6® |
Recombinant thrombin | | ||||||
| Synthon B.V. | Nov. 2008 |
PER.C6® |
Biosimilar protein | | ||||||
| Development Center for Biotechnology (Taiwan) | Mar. 2007 |
PER.C6® |
Undisclosed proteins |
| ||||||
| Talecris Biotherapeutics Inc. | Sep. 2008 |
PER.C6® |
Undisclosed protein |
| ||||||
|
Talecris Biotherapeutics Inc. |
Dec. 2008 |
PER.C6® |
Undisclosed proteins | | ||||||
|
Thrombolytic Science Int. Inc |
Oct. 2009 | PER.C6® |
Undisclosed protein |
| ||||||
|
Yeda R&D Company Ltd |
May 2010 |
PER.C6® |
Antibodies against Hepatitis B |
| ||||||
Gene Therapy
|
Partner/ Licensee |
Starting date |
|
Technology platform |
|
Area |
|
Development stage | |||
|
Ark Therapeutics |
Jan. 2006 |
PER.C6® |
Portfolio |
| ||||||
| Broadvector Limited | Dec. 2008 |
PER.C6® |
Adenovirus-vectored product |
| ||||||
| Cancer Research UK Centre | Jan. 2010 |
PER.C6® |
Oncology |
| ||||||
|
Merck & Co., Inc. |
Nov. 1998 |
PER.C6® |
Portfolio |
| ||||||
| Momotaro-Gene Inc. | Aug. 2009 |
PER.C6® |
Prostate cancer |
| ||||||
|
NeoTropix Inc. |
|
Mar. 2004 |
|
PER.C6® |
|
Oncology |
|
| ||
|
TapImmune |
|
Aug. 2003 |
|
PER.C6® |
|
Portfolio |
|
| ||
|
Transgene SA |
|
April 2001 |
|
PER.C6® |
|
Portfolio |
|
| ||
Alliances with Manufacturing Contractors
|
Partner/ Licensee |
|
Starting date |
|
Technology platform |
|
Development stage | ||
| Bioceros | Jan. 2009 |
PER.C6® |
Cell line generation services | |||||
|
Biochrom AG |
Nov. 2008 |
PER.C6® / PERMEXCIS® |
Medium development | |||||
|
Cambrex (acquired by Lonza Ltd.) |
|
Aug. 2004 |
|
PER.C6® |
|
Medium development | ||
|
Invitrogen Corp. |
June 2003 |
PER.C6® |
Medium development | |||||
| Eden Biodesign Ltd. | Oct. 2010 |
PER.C6® |
Manufacturing services for vaccines and gene therapies | |||||
| JRH Biosciences Inc. (acquired by Sigma Aldrich Corp.) | May 2004 |
PER.C6® |
Medium development recombinant vaccines | |||||
| KBI Biopharma | Jan. 2009 |
PER.C6® |
Cell line generation services | |||||
|
Lonza Verviers Sprl/Lonza Sales Ltd. |
Nov. 2008 |
PER.C6® / PERMEXCIS® |
Medium development
| |||||
|
SAFC Pharma |
Dec. 2001 |
PER.C6® |
Recombinant vaccines & gene therapy products (US) | |||||
|
Sigma-Aldrich Corp. |
|
Dec. 2003 |
|
PER.C6® |
|
Medium development | ||
| Thermo Fischer Scientific Inc. | Dec. 2003 |
PER.C6® |
Medium development | |||||
| Vivante GMP Solutions Inc. | May 2009 |
PER.C6® |
Manufacturing services and gene therapeutics | |||||
E-MAIL THIS PAGE
PRINT THIS PAGE